TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21945698

Group type: EXPERIMENTAL
Intervention: Tdap-B (Boostrix)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tdap-A (Adacel)
Number of subjects: 0
Study: 21945953

Group type: EXPERIMENTAL
Intervention: Infliximab therapy discontinued
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Infliximab re-treatment after relapse
Number of subjects: 115
Study: 21947381

Group type: EXPERIMENTAL
Intervention: eGFRcre (CKD-EPI)
Number of subjects: 448
Study: 21947399

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 36
Study: 21948234

Group type: EXPERIMENTAL
Intervention: T1/T2 cells (5 × 10(6) cells/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Historical controls (identically treated except for T1/T2 product infusions)
Number of subjects: 9
Study: 21949169

Group type: EXPERIMENTAL
Intervention: Primary care physicians' views on care levels
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Factors leading to aggressive practice
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Financial incentives impact on diagnostic testing
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Variation in physician practices
Number of subjects: 627
Study: 21949230

Group type: EXPERIMENTAL
Intervention: Inhibition of IL-1beta
Number of subjects: 0
Study: 21951550

Group type: EXPERIMENTAL
Intervention: COPD and asthma
Number of subjects: 119

Group type: COMPARATOR
Intervention: COPD alone
Number of subjects: 119
Study: 21951596

Group type: EXPERIMENTAL
Intervention: HIV antiretroviral therapy
Number of subjects: 0
Study: 21951809

Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IBS-constipation patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 12
Study: 21951987

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 8
Study: 21953248

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily and bevacizumab 10 mg/kg on days 1 and 15 every 28 days
Number of subjects: 27
Study: 21953853

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) therapy for patients with RVT for up to 2 years
Number of subjects: 409

Group type: COMPARATOR
Intervention: No VKA therapy for patients without RVT
Number of subjects: 409
Study: 21955300

Group type: EXPERIMENTAL
Intervention: Cardiac arrest patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients with a proven genetic cause
Number of subjects: 100
Study: 21955650

Group type: EXPERIMENTAL
Intervention: Higher intake of saturated fat
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Higher intake of trans fat
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Higher intake of added sugar
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Lower intake of vegetable and fruit fiber
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Higher vegetable and fruit fiber intake (in participants with family history of type 2 diabetes)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Lower carbohydrate intake
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Higher total fat intake
Number of subjects: 205
Study: 21956038

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difference between Bi-V pacing and preimplantation QRS width
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LV-paced QRS width
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LV-paced QRS width ≤ 200 ms
Number of subjects: 0
Study: 21956423

Group type: EXPERIMENTAL
Intervention: Fructose-sweetened beverages
Number of subjects: 31

Group type: COMPARATOR
Intervention: Glucose-sweetened beverages
Number of subjects: 31
Study: 21956955

Group type: COMPARATOR
Intervention: C-IFAZn
Number of subjects: 780

Group type: COMPARATOR
Intervention: C-IFA
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: M-IFAZn + C-IFA or C-IFAZn
Number of subjects: 780
Study: 21958326

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) in the highest quartile (Q4)
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) in TnT positive patients (TnT > 0.01 ng/mL) in the highest quartile (Q4)
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: High-sensitive C-reactive protein (hsCRP) in the highest quartile (Q4)
Number of subjects: 982

Group type: COMPARATOR
Intervention: B-type natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP)
Number of subjects: 982
Study: 21958674

Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based practices (EBPs)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Collaboration among systems leaders
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Social networks of information and advice
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Advice seeking and network structure
Number of subjects: 176

Group type: COMPARATOR
Intervention: Counties that decided not to implement a specific EBP
Number of subjects: 176
Study: 21959320

Group type: EXPERIMENTAL
Intervention: ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ABSORB BVS
Number of subjects: 30
Study: 21960318

Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil)
Number of subjects: 154
Study: 21963211

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 21963957

Group type: EXPERIMENTAL
Intervention: Artificial neural network-based approach to endoscopic ultrasound elastography
Number of subjects: 258
Study: 21964801

Group type: EXPERIMENTAL
Intervention: Panobinostat 10 mg/m²
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Panobinostat 15 mg/m²
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg/m²
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Panobinostat (all doses)
Number of subjects: 14
Study: 21965374

Group type: EXPERIMENTAL
Intervention: DEX-brief (2 mcg/kg bolus over 10 minutes)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DEX-prolong (2 mcg/kg bolus plus 1 mcg/kg/hr infusion as needed)
Number of subjects: 17
Study: 21965811

Group type: EXPERIMENTAL
Intervention: 11-sign algorithm
Number of subjects: 7587

Group type: EXPERIMENTAL
Intervention: 6-sign algorithm
Number of subjects: 7587

Group type: EXPERIMENTAL
Intervention: YIS7 algorithm
Number of subjects: 7587
Study: 21966356

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INFγ)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Interferon-gamma-induced protein 10 (IP10)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST)
Number of subjects: 813
Study: 21966427

Group type: EXPERIMENTAL
Intervention: SNP rs1898671
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in ex-smokers
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in never-smokers
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Haplotype involving SNP rs1898671
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in independent cohort study
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in ex-smokers in independent cohort study
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: SNP rs1898671 in never-smokers in independent cohort study
Number of subjects: 599
Study: 21967976

Group type: EXPERIMENTAL
Intervention: Intravenous clofarabine 40 mg/m(2) per day, cyclophosphamide 440 mg/m(2) per day, etoposide 100 mg/m(2) per day for 5 consecutive days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intravenous clofarabine, cyclophosphamide, and etoposide
Number of subjects: 25
Study: 21968545

Group type: EXPERIMENTAL
Intervention: Regadenoson (0.4 mg/5 ml bolus)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adenosine (140 μg/kg/min)
Number of subjects: 30
Study: 21969340

Group type: EXPERIMENTAL
Intervention: MRI at 1.5 T with pacing mode changed to asynchronous for pacemaker-dependent patients and to demand for others
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: MRI at 1.5 T
Number of subjects: 438
Study: 21969517

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m² plus gemcitabine 1,000 mg/m²
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus gemcitabine
Number of subjects: 67
Study: 21971123

Group type: EXPERIMENTAL
Intervention: Surgery with incidental durotomy
Number of subjects: 389

Group type: COMPARATOR
Intervention: Surgery without incidental durotomy
Number of subjects: 389
Study: 21973271

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study: 21974483

Group type: EXPERIMENTAL
Intervention: Modified music exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard music exposure parameters
Number of subjects: 0
Study: 21974763

Group type: EXPERIMENTAL
Intervention: HBP Knowledge Test (HKT)
Number of subjects: 885
Study: 21975150

Group type: EXPERIMENTAL
Intervention: Hip Resurfacing Arthroplasty (HRA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Total Hip Replacement (THR)
Number of subjects: 84
Study: 21975153

Group type: EXPERIMENTAL
Intervention: Elective ventral hernia repair (study group)
Number of subjects: 2258

Group type: COMPARATOR
Intervention: Control group (no poor outcomes)
Number of subjects: 2258
Study: 21975221

Group type: EXPERIMENTAL
Intervention: Blood manganese levels in patients with hepatic encephalopathy (median, range) [28, (17-39.5) μg/L] for those who died after 6 months follow-up.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Blood manganese levels in patients with hepatic encephalopathy (median, range) [13.5, (10.5-32) μg/L] for those who survived after 6 months follow-up.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Blood manganese levels in patients with hepatic encephalopathy (median, range) [20.5, (10.5-39.5) μg/L].
Number of subjects: 9
Study: 21975322

Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver lasting less than 120 minutes (Group 1)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Intermittent Pringle maneuver lasting more than 120 minutes (Group 2)
Number of subjects: 189
Study: 21976132

Group type: EXPERIMENTAL
Intervention: Dasatinib 50 to 120 mg once daily and docetaxel 60 to 75 mg/m² every 21 days (phase 1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily and docetaxel 75 mg/m² every 21 days (phase 2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Single-agent dasatinib after docetaxel discontinuation
Number of subjects: 46
Study: 21976540

Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258) at 400 mg/d
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258)
Number of subjects: 47
Study: 21976672

Group type: EXPERIMENTAL
Intervention: Barasertib 1200 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Barasertib 800 mg, 1200 mg, and 1600 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Barasertib
Number of subjects: 64
Study: 21976674

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning and transplantation of unrelated umbilical cord blood and CD34(+) stem cells from a haploidentical family member
Number of subjects: 45
Study: 21977353

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (200 to 400 mg/d)
Number of subjects: 1395
Study: 21977355

Group type: EXPERIMENTAL
Intervention: Physician counseling that medication use was safe despite FDA warning
Number of subjects: 96

Group type: COMPARATOR
Intervention: FDA warning reporting a 5% chance of birth defects with use
Number of subjects: 96
Study: 21978972

Group type: EXPERIMENTAL
Intervention: DWI-FLAIR mismatch
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: DWI
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: FLAIR
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Interobserver agreement for FLAIR imaging
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Multivariate regression analysis
Number of subjects: 543
Study: 21981988

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 5298

Group type: COMPARATOR
Intervention: No statin treatment (Control)
Number of subjects: 5298
Study: 21982118

Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Elacridar
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: BAY 11-7082
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3
Study: 21982342

Group type: EXPERIMENTAL
Intervention: L-BLP25 plus best supportive care (BSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 0
Study: 21982650

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes substudy in ≥1,500 patients
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Real-world treatment including rate and rhythm control, stroke prevention, transitions to new therapies
Number of subjects: 10000
Study: 21983216

Group type: EXPERIMENTAL
Intervention: PCV13 (2 doses for group 1, 1 dose for group 2)
Number of subjects: 284
Study: 21983625

Group type: EXPERIMENTAL
Intervention: BEAT Cancer physical activity behavior change intervention
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study: 21984541

Group type: COMPARATOR
Intervention: Diabetic patients
Number of subjects: 30
Study: 21984804

Group type: EXPERIMENTAL
Intervention: GD2-CAR T cells (CAR-ATCs and CAR-CTLs)
Number of subjects: 19
Study: 21985945

Group type: EXPERIMENTAL
Intervention: Whole tumor or lymph node (Whole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SliceMax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 95Max
Number of subjects: 0
Study: 21986637

Group type: EXPERIMENTAL
Intervention: BM MSCs derived from patients with critical leg ischemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21986722

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 4 mg/ml-min), Irinotecan (340 mg/m2 for patients on EIAEDs, 125 mg/m2 for others), Bevacizumab (10 mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carboplatin, Irinotecan, Bevacizumab
Number of subjects: 40
Study: 21986736

Group type: EXPERIMENTAL
Intervention: Women (35% developed ARDS)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Men (25% developed ARDS)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Patients with ARDS (both genders)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Proinflammatory sex hormone profile (low testosterone and high estradiol)
Number of subjects: 648
Study: 21987241

Group type: EXPERIMENTAL
Intervention: Maraviroc 150 mg twice daily for 14 days
Number of subjects: 12
Study: 21989407

Group type: EXPERIMENTAL
Intervention: e-Cigarette
Number of subjects: 40
Study: 21990384

Group type: EXPERIMENTAL
Intervention: Myocardial salvage index (MSI) ≥ median
Number of subjects: 208

Group type: COMPARATOR
Intervention: Myocardial salvage index (MSI) < median
Number of subjects: 208
Study: 21991891

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoids
Number of subjects: 935
Study: 21991892

Group type: EXPERIMENTAL
Intervention: Bronchodilator administration
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Patients with emphysema
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Patients with bronchodilator reversibility
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 2163
Study: 21992630

Group type: EXPERIMENTAL
Intervention: Zilver PTX drug-eluting stent
Number of subjects: 787
Study: 21992853

Group type: EXPERIMENTAL
Intervention: Aflibercept 6 mg/kg intravenously plus docetaxel 75 mg/m(2) intravenously, every 3 weeks
Number of subjects: 46
Study: 21993671

Group type: EXPERIMENTAL
Intervention: VHL(R200W) homozygotes
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Phlebotomy therapy in VHL(R200W) homozygotes
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low ferritin concentration in VHL(R200W) homozygotes
Number of subjects: 120

Group type: COMPARATOR
Intervention: Controls with normal VHL alleles
Number of subjects: 120
Study: 21994418

Group type: EXPERIMENTAL
Intervention: ALT-801 at 0.04 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: ALT-801 treatment
Number of subjects: 26
Study: 21994964

Group type: EXPERIMENTAL
Intervention: Dietary intervention to reduce fat and increase fiber intake during childhood and adolescence
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 230
Study: 21995267

Group type: EXPERIMENTAL
Intervention: 4-layer bandaging (4LB)
Number of subjects: 424

Group type: COMPARATOR
Intervention: short-stretch bandaging (SSB)
Number of subjects: 424
Study: 21995329

Group type: EXPERIMENTAL
Intervention: Community and hospital-based care management and coordination intervention
Number of subjects: 19
Study: 21996385

Group type: EXPERIMENTAL
Intervention: In-hospital major bleeding (IHMB)
Number of subjects: 3602
Study: 21997132

Group type: EXPERIMENTAL
Intervention: Standardized adjuvant treatment in controlled clinical trials
Number of subjects: 14611
Study: 21997144

Group type: EXPERIMENTAL
Intervention: Internet usage for health/medical information
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Internet usage for children's health/medical information
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Socioeconomic correlates of computer ownership
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Internet usage among parents with ≤ a college degree or BMI <25 kg/m(2)
Number of subjects: 470
Study: 21997548

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pathologist's assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Automated software quantification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher liver fat content (assessed by MRI) in patients
Number of subjects: 0
Study: 21998067

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 21998698

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) vaccine
Number of subjects: 407

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Combined data from RTS,S/AS01(E) and control vaccinees
Number of subjects: 407
Study: 21999176

Group type: EXPERIMENTAL
Intervention: Prefilled pen for IM IFNβ-1a administration
Number of subjects: 71
Study: 21999346

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting therapy (RLAT)
Number of subjects: 532
Study: 21999370

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting therapy (RLAT)
Number of subjects: 435
Study: 22002488

Group type: EXPERIMENTAL
Intervention: One-unit umbilical cord blood transplantation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Two-unit umbilical cord blood transplantation
Number of subjects: 50
Study: 22002941

Group type: EXPERIMENTAL
Intervention: Methylation-promoting dietary supplements (betaine, metafolin, creatine, and vitamin B(12))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group from a previous randomized double-blind trial using folic acid and betaine
Number of subjects: 0
Study: 22003071

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1) plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) plus pertuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab plus a taxane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1) compared with lapatinib plus capecitabine
Number of subjects: 0
Study: 22003107

Group type: EXPERIMENTAL
Intervention: CACD patients (n=30)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Early AMD patients (n=19)
Number of subjects: 62

Group type: COMPARATOR
Intervention: AMD patients with GA (n=13)
Number of subjects: 62

Group type: COMPARATOR
Intervention: AMD patients (n=19)
Number of subjects: 62
Study: 22003383

Group type: EXPERIMENTAL
Intervention: NMRC-M3V-Ad-PfCA vaccine, 2×10^10 particle units (1×10^10 each construct)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NMRC-M3V-Ad-PfCA vaccine, 5-fold higher dose (10×10^10 particle units)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NMRC-M3V-Ad-PfCA vaccine
Number of subjects: 12
Study: 22003411

Group type: EXPERIMENTAL
Intervention: NMRC-MV-Ad-PfC vaccine (adenovirus vector encoding CSP), 1 x 10^10 particle units per dose, two doses 16 weeks apart
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: NMRC-MV-Ad-PfC vaccine (adenovirus vector encoding CSP)
Number of subjects: 14
Study: 22004373

Group type: EXPERIMENTAL
Intervention: Non-surgical treatment by a doctor
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Spontaneous healing
Number of subjects: 198

Group type: COMPARATOR
Intervention: Routine non-selective surgical intervention
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Intensive surveillance and early surgical intervention
Number of subjects: 198
Study: 22004880

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 0
Study: 22005144

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (PCT) with surgery, based mainly on a fluorouracil-platinum doublet or triplet regimen.
Number of subjects: 924

Group type: COMPARATOR
Intervention: Primary surgery (S) without perioperative chemotherapy.
Number of subjects: 924

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy after surgery in the S group.
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy after surgery in the PCT group.
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: PCT as a treatment.
Number of subjects: 924
Study: 22005150

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy (TT)
Number of subjects: 8032

Group type: COMPARATOR
Intervention: Bilateral subtotal thyroidectomy (BST)
Number of subjects: 8032
Study: 22005184

Group type: EXPERIMENTAL
Intervention: Greater RRV(food)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Dietary disinhibition
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Dietary restraint
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: RRV(food)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 273
Study: 22005709

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing of maternal plasma DNA
Number of subjects: 4664